(Q38050335)

27 August 2017

title

mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis (English)

1 reference

27 August 2017

0 references

1 reference

Lucia Lisi

2

0 references

Cinzia Dello Russo

object named as

Cinzia Dello Russo

series ordinal

1

0 references

Pierluigi Navarra

object named as

Pierluigi Navarra

series ordinal

4

0 references

author name string

Douglas L Feinstein

series ordinal

3

1 reference

27 August 2017

publication date

8 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

61

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

301-311

1 reference

Mammalian target of rapamycin (mTOR) activation increases axonal growth capacity of injured peripheral nerves

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

mTOR regulates memory CD8 T-cell differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Calcineurin-inhibitor-sparing immunosuppressive protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Cellular localization of metabotropic glutamate receptors in cortical tubers and subependymal giant cell tumors of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Chemotropic responses of retinal growth cones mediated by rapid local protein synthesis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Serotonin increases phosphorylation of synaptic 4EBP through TOR, but eukaryotic initiation factor 4E levels do not limit somatic cap-dependent translation in aplysia neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Noradrenaline enhances the expression of the neuronal monocarboxylate transporter MCT2 by translational activation via stimulation of PI3K/Akt and the mTOR/S6K pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

PTEN inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The Rheb-mTOR pathway is upregulated in reactive astrocytes of the injured spinal cord.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Pharmacological inhibition of Akt and downstream pathways modulates the expression of COX-2 and mPGES-1 in activated microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Target of rapamycin (TOR): balancing the opposing forces of protein synthesis and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Functional genomic analysis of oligodendrocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rapamycin is a neuroprotective treatment for traumatic brain injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Peroxisome proliferator-activated receptor-gamma agonists prevent experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Use of rapamycin in the induction of tolerogenic dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Chronic progressive multiple sclerosis - pathogenesis of neurodegeneration and therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Constitutively active Akt induces enhanced myelination in the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Mammalian target of rapamycin (mTOR): conducting the cellular signaling symphony

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Intrinsic regulation of brain inflammatory responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Clinical characteristics of multiple sclerosis with early onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Elevated phosphatidylinositol 3,4,5-trisphosphate in glia triggers cell-autonomous membrane wrapping and myelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Erk1/2 MAPK and mTOR signaling sequentially regulates progression through distinct stages of oligodendrocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The receptor SIGIRR suppresses Th17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rapamycin: something old, something new, sometimes borrowed and now renewed

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

mTOR signaling: at the crossroads of plasticity, memory and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Role of TSC-mTOR pathway in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Catalase induced expression of inflammatory mediators via activation of NF-kappaB, PI3K/AKT, p70S6K, and JNKs in BV2 microglia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Control of dendritic arborization by the phosphoinositide-3'-kinase-Akt-mammalian target of rapamycin pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The growing role of mTOR in neuronal development and plasticity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

New treatment strategies in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Dopaminergic pathway reconstruction by Akt/Rheb-induced axon regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Dendritic mRNA targeting and translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Tuberous sclerosis: from tubers to mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Experimental models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Insulin promotes dendritic spine and synapse formation by the PI3K/Akt/mTOR and Rac1 signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Glutamatergic regulation of the p70S6 kinase in primary mouse neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The mTOR kinase inhibitor rapamycin decreases iNOS mRNA stability in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rapamycin reduces clinical signs and neuropathic pain in a chronic model of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

PTEN deletion enhances the regenerative ability of adult corticospinal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Hypoxia-induced iNOS expression in microglia is regulated by the PI3-kinase/Akt/mTOR signaling pathway and activation of hypoxia inducible factor-1alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Molecular mechanisms of mTOR-mediated translational control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Response of a neuronal model of tuberous sclerosis to mammalian target of rapamycin (mTOR) inhibitors: effects on mTORC1 and Akt signaling lead to improved survival and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

mTOR at the crossroads of T cell proliferation and tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rapamycin impairs antigen uptake of human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Pain associated with multiple sclerosis: systematic review and proposed classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

mTORC2 can associate with ribosomes to promote cotranslational phosphorylation and stability of nascent Akt polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Akt/mammalian target of rapamycin signaling pathway regulates neurite outgrowth in cerebellar granule neurons stimulated by methylcobalamin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

mTOR/S6 kinase pathway contributes to astrocyte survival during ischemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Cell signaling. mTOR, unleashed

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Regulation of cap-dependent translation by insulin-like growth factor-1 in neuronal cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rapamycin activates autophagy and improves myelination in explant cultures from neuropathic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The biology and clinical relevance of the PTEN tumor suppressor pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Erythropoietin and Wnt1 govern pathways of mTOR, Apaf-1, and XIAP in inflammatory microglia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Brain-derived neurotrophic factor enhances the basal rate of protein synthesis by increasing active eukaryotic elongation factor 2 levels and promoting translation elongation in cortical neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Pituitary adenylyl cyclase-activating polypeptide is an intrinsic regulator of Treg abundance and protects against experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

A rapamycin-sensitive signaling pathway contributes to long-term synaptic plasticity in the hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Immunoregulatory functions of mTOR inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Rapamycin inhibits mTORC1, but not completely.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Targeting mammalian target of rapamycin (mTOR) for health and diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Activation of the mammalian target of rapamycin (mTOR) is essential for oligodendrocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Proteomic identification of novel targets regulated by the mammalian target of rapamycin pathway during oligodendrocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The PI3K/Akt/mTOR pathway in innate immune cells: emerging therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

The multiple facets of mTOR in immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Insulin promotes rat retinal neuronal cell survival in a p70S6K-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

PI3K/Akt/mTOR signaling regulates glutamate transporter 1 in astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

TOR signaling in growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Structure of the human mTOR complex I and its implications for rapamycin inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Receptor signaling in immune cell development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

Synergism between sirolimus and 1,25-dihydroxyvitamin D3 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

7 January 2021

Regulation and function of mTOR signalling in T cell fate decisions

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

7 January 2021

Inflammation and neurodegenerative diseases

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

7 January 2021

Kinetics and cellular origin of cytokines in the central nervous system: insight into mechanisms of myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

7 January 2021

Inhibition of the immune response by rapamycin, a new antifungal antibiotic

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

7 January 2021

Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosuppressants

1 reference

https://api.crossref.org/works/10.1002%2FGLIA.22433

7 January 2021

Identifiers

DOI

10.1002/GLIA.22433

1 reference

27 August 2017

1 reference